Category Archives: Cell Biology

Don’t mess with meiosis: Study suggests how reproductive health influences overall health and aging – EurekAlert

image:A young C. elegans adult glowing green where a protein has been linked to a fluorescent tag and filled with soon-to-be-laid eggs that appear as dark spheres in the mothers body. Disruption of meiosis, a process on which the creation of these eggs depends, shortens the animals entire life and accelerates its aging. view more

Credit: Scott Keith & Arjumand Ghazi

New research in an animal model of aging suggests a possible mechanism for why people with early menopause or other genetic conditions affecting the reproductive system are more likely to get cardiovascular disease, diabetes and dementia.

Disrupting a process called meiosis in reproductive cells of C. elegans led to a decline in the worms health and triggered an accelerated aging gene signature similar to that of aging humans, according to the new study, led by University of Pittsburgh and UPMC researchers and published in Aging Cell.

This study is exciting because its the first direct evidence that manipulating the health of reproductive cells leads to premature aging and a decline in healthspan, said senior author Arjumand Ghazi, Ph.D., associate professor of pediatrics, developmental biology, and cell biology and physiology at Pitt and UPMC Childrens Hospital of Pittsburgh. The implications of this finding are profound: It suggests that the status of the reproductive system is important not simply to produce children, but also for overall health.

While the effects of aging on fertility are well-established, research over the last two decades has begun to reveal that reproductive fitness, in turn, affects aging and health in people. The problem is that directly testing this kind of cause and effect in humans is difficult. So Ghazi and her team turned to a tiny nematode worm called Caenorhabditis elegans, an ideal system in which to study aging because it has a short lifespan cradle to grave takes just three weeks and shares many genetic pathways with people.

The researchers looked at meiosis, a type of cell division that occurs only in cells destined to become sperm or egg and is seen in all species from yeast to humans. They found that animals with mutations in meiosis genes had shorter lifespans than their normal counterparts. The mutants also showed worse measures of general health, including premature declines in mobility, muscle function and memory.

The exciting part of this healthspan work was that these animals also showed signs of disrupted protein homeostasis, said Ghazi. Disruption to the balance of proteins inside cells is at the heart of age-related neurodegenerative diseases, like Alzheimers disease.

When the researchers improved protein homeostasis in the worms, some loss of lifespan was prevented. These findings point to disrupted proteostasis as a key mechanism linking reproductive health and aging.

Next, the team looked at gene expression changes in C. elegans. At day 1 of adulthood, meiosis mutants expressed genes that were remarkably similar to those normal worms wouldnt express until day 10.

In human terms, its like someone in their early 20s having the physical appearance, physiology and gene signatures of a 70-year-old, explained Ghazi. Messing with meiosis has dramatic effects on healthspan and accelerates aging in C. elegans.

Many of the same genes control aging in worms and humans. So the researchers asked if the meiosis mutants gene signature had any similarities with genes of aging humans. They found that this was, indeed, the case a notable finding as it suggests that disrupting the reproductive system may produce similar changes from worms to humans.

Since C. elegans can be used to make fundamental discoveries not possible in humans and more complex systems, this discovery opens up great possibilities for understanding how the reproductive system shapes aging, said Ghazi.

She is now planning to partner with UPMC Magee-Womens Hospital and Magee-Womens Research Institute to further probe this question in human patients who, due to genetic disease, undergo extremely premature menopause and exhibit complications such as heart disease, autoimmune disorders and osteoporosis.

Informed by our work in C. elegans, we want to develop a panel of age-related genes and use this to screen patients blood and saliva, said Ghazi. If we see evidence of the same genes being elevated in patients, it would be a major first step toward extending such studies to women who undergo early menopause and early infertility.

Ghazi hopes that eventually this work could inform tests for early detection of health impairments triggered by reproductive abnormalities and new treatments or repurposing of existing drugs to treat such age-related diseases.

Other authors who contributed to this study are Julia A. Loose, Ph.D., Francis R. G. Amrit, Ph.D., Thayjas Patil, and Judith L. Yanowitz, Ph.D., all of Pitt or UPMC.

This work was supported by the National Institutes of Health (R01AG051659, 1R56AG066682 and R01GM104007).

##

Experimental study

Animals

Meiotic dysfunction accelerates somatic aging in Caenorhabditis elegans

29-Sep-2022

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

Follow this link:
Don't mess with meiosis: Study suggests how reproductive health influences overall health and aging - EurekAlert

Is the Spatial Revolution the Future of Single-Cell Biology? – Genetic Engineering & Biotechnology News

Broadcast Date:October 19, 2022Time:8:00 am PT, 11:00 am ET, 17:00 CET

Spatial biology has all the hallmarks of the next omics revolution. Although the concept of studying cells within the context of their location in tissues has been around for decades, the recent emergence of new technologies is ushering the field into a new era.

In this episode of GEN Live, well talk to two experts,Dr. Chris MasonandDr. Jasmine Plummer, about where spatial biology is now and where it might be heading. Its early days, but the potential is vast. Well discuss how understanding cellular organization at the single-cell level might be the next big wave.

A live Q&A session will follow the presentation, offering you a chance to pose questions to our expert panelists.

Webinar produced with support from:

Read the original here:
Is the Spatial Revolution the Future of Single-Cell Biology? - Genetic Engineering & Biotechnology News

BREAKTHROUGH TECHNOLOGY FOR IPS-DERIVED CELL THERAPIES TURNED INTO GMP PLATFORM BY TREEFROG THERAPEUTICS & INVETECH – BioSpace

Bordeaux, France /October 11th, 2022TreeFrog Therapeutics,a biotechnology company developing stem cell-derived therapies in regenerative medicine and immuno-oncology based on the biomimetic C-Stem technology platform, and Invetech, a global leader in the development and production ofautomated manufacturing solutionsfor cell and advanced therapies, today announced the delivery of a GMP-grade cell encapsulation device using theC-Stem technology. The machine will be transferred in 2023 to a contract development and manufacturing organization (CDMO) to produce TreeFrogs cell therapy candidate for Parkinsons disease, with the aim of a first-in-human trial in 2024. Over 2023, Invetech will deliver three additional GMP encapsulation devices to support TreeFrogs in-house and partnered cell therapy programs in regenerative medicine and immuno-oncology.

Blending microfluidics and stem cell biology, TreeFrogs C-Stem technology generates alginate capsules seeded with induced pluripotent stem cells (iPSCs) at very high speed. Engineered to mimic the in vivo stem cell niche, the capsules allow iPSCs to grow exponentially in 3D, and to differentiate into ready-to-transplant functional microtissues. And because alginate is both porous and highly resistant, encapsulated iPSCs can be expanded and differentiated in large-scale bioreactors without suffering from impeller-induced shear stress.

TreeFrog Therapeutics introduces a breakthrough technology for cell therapy, which impacts scale, quality, as well as the efficacy and safety potential of cellular products. Automating this disruptive technology and turning it into a robust GMP-grade instrument is a tremendous achievement for our team. This deliverable is the result of a very fruitful and demanding collaboration with TreeFrogs engineers in biophysics and bioproduction over the past four years. Were now eager to learn how the neural microtissues produced with C-Stem will perform in the clinic. Anthony Annibale, Global VP Commercial at Invetech.

Started in 2019, the collaboration between TreeFrog and Invetech led to the delivery of a prototype in October 2020. With this research-grade machine, TreeFrog demonstrated the scalability of C-Stem, moving within six months from milliliter-scale to 10-liter bioreactors. In June 2021, the company announced the production of two single-batches of 15 billion iPSCs in 10L bioreactors with an unprecedented 275-fold amplification per week, striking reproducibility and best-in-class cell quality. The new GMP-grade device delivered by Invetech features the same technical specifications. The machine generates over 1,000 capsules per second, allowing to seed bioreactors from 200mL to 10L. However, the device was entirely redesigned to fit bioproduction standards.

With the GMP device, our main challenge was to minimize the learning curve for operators, so as to facilitate tech transfer. Invetech and our team did an outstanding job in terms of automation and industrial design to make the device both robust and easy to use. As an inventor, I am so proud of the journey of the C-Stem technology. Many elements have been changed and improved on the way, and now comes the time to put the platform in the hands of real-world users to make real products. Kevin Alessandri, Ph.D., co-founder and chief technology officer, TreeFrog Therapeutics

In October 2020, we announced that we were planning for the delivery of a GMP encapsulation device by the end of 2022. Exactly two years after, were right on time. I guess this machine testifies to the outstanding execution capacity of TreeFrog and Invetech. But more importantly, this machine constitutes a key milestone. Our platform can now be used to manufacture clinical-grade cell therapy products. Our plan is to accelerate the translation of our in-house and partnered programs to the clinic, with a focus on immuno-oncology and regenerative medicine applications. Frederic Desdouits, Ph.D., chief executive officer, TreeFrog Therapeutics

About Invetech

For pathfinders in cell and gene therapy striving to accelerate next-generation care, Invetech delivers robust, scalable and cost-effectivemanufacturing systemsfor clinical through to high-volume commercial production. Since 2003, Invetechs Cell Therapy Group has provided Assured Pathways to the commercial manufacturing of cell, gene and tissue therapies, including peripheral and precursor materials such as viral vector and media. Invetech configures manufacturing systems to address client process demands, building from portfolio of proven modules and platform technology. Invetech is a globally recognized leader in life science automation, and a member of the Fortive (NYSE: FTV) group of companies.invetechgroup.com

About TreeFrog Therapeutics

TreeFrog Therapeutics is a French-based biotech company aiming to unlock access to cell therapies for millions of patients. Bringing together over 100 biophysicists, cell biologists and bioproduction engineers, TreeFrog Therapeutics raised $82M over the past 3 years to advance a pipeline of stem cell-based therapies in immuno-oncology and regenerative medicine. In 2022, the company opened technological hubs in Boston, USA, and Kobe, Japan, with the aim of driving the adoption of the C-StemTM platform and establish strategic alliances with leading academic, biotech and industry players in the field of cell therapy.

http://www.treefrog.fr

Media Contact

Pierre-Emmanuel Gaultier

TreeFrog Therapeutics+ 33 6 45 77 42 58

pierre@treefrog.fr

More:
BREAKTHROUGH TECHNOLOGY FOR IPS-DERIVED CELL THERAPIES TURNED INTO GMP PLATFORM BY TREEFROG THERAPEUTICS & INVETECH - BioSpace

DiPersio recognized for key discoveries in cancer biology, treatment Washington University School of Medicine in St. Louis – Washington University…

Visit the News Hub

Foundation honors leading oncologist for outstanding work on leukemia

DiPersio

John F. DiPersio, MD, PhD, the Virginia E. and Sam J. Golman Endowed Professor of Oncology and director of the Division of Oncology at Washington University School of Medicine in St. Louis, is being recognized by the American Italian Cancer Foundation with the 2022 Prize for Scientific Excellence in Medicine.

DiPersio, who also serves as deputy director of Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, is one of two award recipients this year and will be recognized Nov. 9 in New York, along with Guillermina (Gigi) Lozano, PhD, of MD Anderson Cancer Center.

The American Italian Cancer Foundation gives the annual Prize for Scientific Excellence in Medicine to global leaders in scientific research who have made key discoveries in cancer biology, prevention, diagnosis and treatment.

DiPersio is a leader in the field in understanding and developing novel therapies for leukemia, including methods to optimize CAR-T cell therapies, a type of cell-based immunotherapy that attacks cancer cells. His work also includes improving outcomes after stem cell transplantation, including novel methods of stem cell mobilization, and for the management of graft-versus-host disease, a sometimes life-threatening condition that some patients develop after a stem cell transplant.

More:
DiPersio recognized for key discoveries in cancer biology, treatment Washington University School of Medicine in St. Louis - Washington University...

Thirdhand smoke exposure elevates biomarkers associated with the initiation of skin diseases – News-Medical.Net

Thirdhand smoke, or THS, comprises the residual pollutants from tobacco smoke that remain on surfaces and in dust after tobacco has been smoked. It can remain on indoor surfaces indefinitely, causing potentially harmful exposure to both smokers and non-smokers.

A team led by researchers at the University of California, Riverside, has found that acute exposure of the skin to THS elevates biomarkers associated with the initiation of skin diseases, such as contact dermatitis and psoriasis.

"We found exposure of human skin to THS initiates mechanisms of inflammatory skin disease, and elevates urinary biomarkers of oxidative harm, which could lead to other diseases, such as cancer, heart disease, and atherosclerosis," said Shane Sakamaki-Ching, a former graduate student at UC Riverside who graduated with a doctoral degree in cell, molecular, and developmental biology in March 2022. "Alarmingly, acute dermal exposure to THS mimics the harmful effects of cigarette smoking."

The study, published in eBioMedicine of The Lancet family of journals, is the first to be performed on humans exposed dermally to THS.

The clinical investigation, which took place at UC San Francisco, involved the participation of 10 healthy, non-smokers who were 22 to 45 years old. For three hours, each participant wore clothing impregnated with THS and either walked or ran on a treadmill for at least 15 minutes each hour to induce perspiration and increase uptake of THS through the skin. The participants did not know the clothing had THS. Blood and urine samples were then collected from the participants at regular intervals to identify protein changes and markers of oxidative stress induced by the THS. Control exposure participants wore clean clothing.

"We found acute THS exposure caused elevation of urinary biomarkers of oxidative damage to DNA, lipids, and proteins, and these biomarkers remained high after the exposure stopped," said Sakamaki-Ching, now a research scientist at Kite Pharma in California, where he leads a stem cell team. "Cigarette smokers show the same elevation in these biomarkers. Our findings can help physicians in diagnosing patients exposed to THS and help develop regulatory policies dealing with remediation of indoor environments contaminated with THS."

Prue Talbot, a professor of cell biology in whose lab Sakamaki-Ching worked, explained that skin is the largest organ to contact THS and may thus receive the greatest exposure.

"There is a general lack of knowledge of human health responses to THS exposure," said Talbot, the paper's corresponding author. "If you buy a used car previously owned by a smoker, you are putting yourself at some health risk. If you go to a casino that allows smoking, you are exposing your skin to THS. The same applies to staying in a hotel room that was previously occupied by a smoker."

The THS exposures that the 10 participants were subjected to were relatively brief and did not cause visible changes in the skin. Nevertheless, the molecular biomarkers in blood that are associated with early-stage activation of contact dermatitis, psoriasis and other skin conditions were elevated.

This underscores the idea that dermal exposure to THS could lead to molecular initiation of inflammation-induced skin diseases."

Shane Sakamaki-Ching, Former Graduate Student at UC Riverside

Next, the researchers plan to evaluate residues left by electronic cigarettes that can come into contact with human skin. They also plan to evaluate larger populations exposed to longer periods of dermal THS.

Sakamaki-Ching and Talbot were joined in the study by Jun Li of UCR, Suzaynn Schick of UC San Francisco, and Gabriela Grigorean of UC Davis.

The study was supported by grants to Talbot and Schick from the Tobacco Related Disease Research Program of California.

Source:

Journal reference:

Sakamaki-Ching, S., et al. (2022) Dermal thirdhand smoke exposure induces oxidative damage, initiates skin inflammatory markers, and adversely alters the human plasma proteome. eBioMedicine. doi.org/10.1016/j.ebiom.2022.104256.

Read more:
Thirdhand smoke exposure elevates biomarkers associated with the initiation of skin diseases - News-Medical.Net

Researchers take new approach to studying the development of the human brain – News-Medical.Net

Researchers at ETH Zurich are growing human brain-like tissue from stem cells and are then mapping the cell types that occur in different brain regions and the genes that regulate their development.

The human brain is probably the most complex organ in the entire living world and has long been an object of fascination for researchers. However, studying the brain, and especially the genes and molecular switches that regulate and direct its development, is no easy task.

To date, scientists have proceeded using animal models, primarily mice, but their findings cannot be transferred directly to humans. A mouse's brain is structured differently and lacks the furrowed surface typical of the human brain. Cell cultures have thus far been of limited value in this field, as cells tend to spread over a large area when grown on a culture dish; this does not correspond to the natural three-dimensional structure of the brain.

A group of researchers led by Barbara Treutlein, ETH Professor at the Department of Biosystems Science and Engineering in Basel, has now taken a new approach to studying the development of the human brain: they are growing and using organoids millimeter-sized three-dimensional tissues that can be grown from what are known as pluripotent stem cells.

Provided these stem cells receive the right stimulus, researchers can program them to become any kind of cell present in the body, including neurons. When the stem cells are aggregated into a small ball of tissue and then exposed to the appropriate stimulus, they can even self-organize and form a three-dimensional brain organoid with a complex tissue architecture.

In a new study just published in Nature, Treutlein and her colleagues have now studied thousands of individual cells within a brain organoid at various points in time and in great detail. Their goal was to characterize the cells in molecular-genetic terms: in other words, the totality of all gene transcripts (transcriptome) as a measure of gene expression, but also the accessibility of the genome as a measure of regulatory activity. They have managed to represent this data as a kind of map showing the molecular fingerprint of each cell within the organoid.

However, this procedure generates immense data sets: each cell in the organoid has 20,000 genes, and each organoid in turn consists of many thousands of cells. "This results in a gigantic matrix, and the only way we can solve it is with the help of suitable programs and machine learning," explains Jonas Fleck, a doctoral student in Treutlein's group and one of the study's co-lead authors. To analyze all this data and predict gene regulation mechanisms, the researchers developed their own program.

We can use it to generate an entire interaction network for each individual gene and predict what will happen in real cells when that gene fails."

Jonas Fleck, doctoral student

The aim of this study was to systematically identify those genetic switches that have a significant impact on the development of neurons in the different regions of brain organoids.

With the help of a CRISPR-Cas9 system, the ETH researchers selectively switched off one gene in each cell, altogether about two dozen genes simultaneously in the entire organoid. This enabled them to find out what role the respective genes played in the development of the brain organoid.

"This technique can be used to screen genes involved in disease. In addition, we can look at the effect these genes have on how different cells within the organoid develop," explains Sophie Jansen, also a doctoral student in Treutlein's group and the second co-lead author of the study.

To test their theory, the researchers chose the GLI3 gene as an example. This gene is the blueprint for the transcription factor of the same name, a protein that docks onto certain sites on DNA in order to regulate another gene. When GLI3 is switched off, the cellular machinery is prevented from reading this gene and transcribing it into an RNA molecule.

In mice, mutations in the GLI3 gene can lead to malformations in the central nervous system. Its role in human neuronal development was previously unexplored, but it is known that mutations in the gene lead to diseases such as Greig cephalopolysyndactyly and Pallister Hall Syndromes.

Silencing this GLI3 gene enabled the researchers both to verify their theoretical predictions and to determine directly in the cell culture how the loss of this gene affected the brain organoid's further development. "We have shown for the first time that the GLI3 gene is involved in the formation of forebrain patterns in humans. This had previously been shown only in mice," Treutlein says.

"The exciting thing about this research is that it lets you use genome-wide data from so many individual cells to postulate what roles individual genes play," she explains. "What's equally exciting in my opinion is that these model systems made in a Petri dish really do reflect developmental biology as we know it from mice."

Treutlein also finds it fascinating how the culture medium can give rise to self-organised tissue with structures comparable to those of the human brain not only at the morphological level but also (as the researchers have shown in their latest study) at the level of gene regulation and pattern formation. "Organoids like this are truly an excellent way to study human developmental biology," she points out.

Research on organoids made up of human cell material has the advantage that the findings are transferable to humans. They can be used to study not only basic developmental biology but also the role of genes in diseases or developmental brain disorders. For example, Treutlein and her colleagues are working with organoids of this type to investigate the genetic cause of autism and of heterotopia; in the latter, neurons appear outside their usual anatomical location in the cerebral cortex.

Organoids may also be used for testing drugs, and possibly for culturing transplantable organs or organ parts. Treutlein confirms that the pharmaceutical industry is very interested in these cell cultures.

However, growing organoids takes both time and effort. Moreover, each clump of cells develops individually rather than in a standardized way. That is why Treutlein and her team are working to improve the organoids and automate their manufacturing process.

Source:

Journal reference:

Fleck, J.S., et al. (2022) Inferring and perturbing cell fate regulomes in human brain organoids. Nature. doi.org/10.1038/s41586-022-05279-8.

Read the rest here:
Researchers take new approach to studying the development of the human brain - News-Medical.Net

Paris-based startup Gourmey uses the Big Idea Ventures accelerator program as a launch pad and goes on to raise the world’s largest cultivated meat…

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

NEW YORK, Oct. 11, 2022 (GLOBE NEWSWIRE) -- French cultivated meat startup Gourmey, who was part of the Big Idea Ventures programs first cohort, has just raised an oversubscribed 48M Series A. This is the worlds largest Series A round for a cultivated meat startup.

Gourmey joined the Big Idea Ventures accelerator program in 2019. The global program facilitated the Paris-based startups move to Singapore, where it worked closely with a dedicated Big Idea Ventures team to lay the foundation for its success.

Andrew D. Ive, Founder and Managing General Partner at Big Idea Ventures, said: Gourmey has gone from strength to strength ever since joining our first cohort. Their agile team, bio-engineering achievements and focus on scalable solutions have allowed them to move faster than others and build the foundation for growth and commercialization. As one of their first investors, we will keep supporting Nicolas and the whole Gourmey team in this next step of their exciting journey.

Gourmey creates sustainable restaurant-grade meats directly from real animal cells, with an initial focus on premium meats and cultivated foie gras as their flagship product. Cultivated meat production consumes significantly less land and water and could cut the climate impact of meat production by up to 92%.

With this financing, the French startups will be opening a 46,000-square-foot commercial production facility and R&D center in Paris, France the largest cultivated meat hub in Europe to fast-track commercialization globally.

About Big Idea Venture (BIV)Big Idea Ventures is a venture firm focused on solving the world's greatest challenges by backing the world's best entrepreneurs, scientists and engineers. To date, BIV has invested in 100+ companies across 22 countries with a focus on protein alternatives and food tech. The investments were made through their New Protein Fund I (NPF I), which is backed by leading food corporations including AAK, Avril, Bel, Bhler, Givaudan, Meiji, Temasek Holdings, and Tyson Foods. New Protein Fund II will be available in Q4 2022 and will build on the successes of NPF I. For more information, visit https://bigideaventures.com

About GourmeyGourmeys mission is to accelerate the worlds transition toward more ethical, sustainable and healthy meat. The company creates sustainable restaurant-grade meats directly from real animal cells, thereby significantly reducing the impact on the environment. Founded in 2019 by CEO Nicolas Morin-Forest (ex-LOral), CTO Dr. Victor Sayous, PhD in molecular biology, and CSO Antoine Davydoff, cell biologist, the company is now a team of 40+ world-class scientists and engineers in the fields of gastronomic and food sciences, bioprocess engineering, and stem cell biology.

Media contact: [emailprotected] High-resolution images and logo of Gourmey: presskit.gourmey.com Find out more: gourmey.com

Read more:
Paris-based startup Gourmey uses the Big Idea Ventures accelerator program as a launch pad and goes on to raise the world's largest cultivated meat...

HHMI Investigator Carolyn Bertozzi Awarded the 2022 Nobel Prize in Chemistry | HHMI – Howard Hughes Medical Institute

Summary

The Royal Swedish Academy of Sciences announced today that HHMI Investigator Carolyn Bertozzi of Stanford University, Morten Meldal of University of Copenhagen, and K. Barry Sharpless of Scripps Research Institute are the recipients of the 2022 Nobel Prize in Chemistry for the development of click chemistry and bioorthogonal chemistry.

The development of ingenious tools for building new molecules has earned three scientists the 2022 Nobel Prize in Chemistry.

Carolyn Bertozzi, a Howard Hughes Medical Institute (HHMI) Investigator at Stanford University, Morten Meldal of University of Copenhagen, and K. Barry Sharpless of Scripps Research Institute have received the award for their work on the development of click chemistry and bioorthogonal chemistry.

Sharpless and Meldal laid the foundation for a functional form of chemistry click chemistry in which molecular building blocks snap together quickly and efficiently. Bertozzi has taken click chemistry to a new dimension and started utilizing it in living organisms.

The Royal Swedish Academy of Sciences announced the news at a press conference earlier today. This years Prize in Chemistry deals with not overcomplicating matters, instead working with what is easy and simple. Functional molecules can be built even by taking a straightforward route, says Johan qvist, Chair of the Nobel Committee for Chemistry.

Bertozzi has been an HHMI Investigator since 2000.

Bertozzi explores ways to reengineer cell surfaces with the goal of controlling the cells interactions. Ultimately, her work may allow investigators to target cancer cells for diagnosis and treatment, for example, or to detect pathogenic bacteria in biological fluid samples.

Carolyn is a role model, mentor, and inspiration to budding chemists everywhere, said Leslie Vosshall, vice president and chief scientific officer at HHMI. What is terrific about Carolyn is that she effortlessly bridges curiosity-driven basic research and therapeutic translation. Her creative application of chemistry to biology has led to rapid development of these ideas to future clinical interventions.

BREAKING NEWS:The Royal Swedish Academy of Sciences has decided to award the 2022 #NobelPrize in Chemistry to Carolyn R. Bertozzi, Morten Meldal and K. Barry Sharpless for the development of click chemistry and bioorthogonal chemistry. pic.twitter.com/5tu6aOedy4

She grew up immersed in science her father was a nuclear physicist at MIT, where she attended summer day camps and later had summer jobs. Still, she seriously considered a career in music (having won awards for compositions and accompanying musicals during her high-school years) before her leanings toward math and science won out.

As a Harvard undergrad biology major, Bertozzi discovered the thrill of organic chemistry during her sophomore year. I wouldnt go out on weekends because I just wanted to read the book and see if I could work the problems, she said. Realizing her calling, she switched her major to chemistry and graduated summa cum laude. (She did find an outlet for her music at Harvard, she played keyboard with guitarist Tom Morello, founder of the rock band Rage Against the Machine.)

After Bertozzi finished her PhD in organic chemistry in 1993 at the University of California, Berkeley, she did something risky. She accepted a postdoctoral fellowship in a cell biology lab, not a chemistry lab. In the decades since, chemists have embraced the value of studying biology by total immersion.

One of Bertozzis research interests is glycosylation, the normal cellular process by which sugars are added to proteins or other molecules. Scientists have known for decades that changes in glycosylation are associated with cancer, inflammation, bacterial infection, and other illnesses. Bertozzi reasoned that if she could develop a way to monitor glycosylation and measure it quickly, simply, and noninvasively, the results would deepen researchers understanding of how cell surface sugars contribute to both health and illness and could open avenues for diagnosing and treating disease.

Toward this goal, she and her colleagues developed a chemical reaction that adds a marker molecule to cell surface sugars, a technique they refined for use in living animals. Their innovative approach, which Bertozzi dubbed bioorthogonal chemistry, uses reagents that react with one another but not with naturally occurring cell surface molecules. Thus, the reagents do not interfere with the sugars ability to carry out their normal signaling functions. Bertozzis team has used the reaction to attach tracers to sugar molecules on cell surfaces in mice. The sugars they targeted are produced in elevated amounts by cancer cells and by inflamed cells.

The teams work suggests that this technique could potentially be used to attach tracers to diseased cells in patients, allowing doctors to pinpoint location of the cells in the body and perhaps even target therapy. The techniques developed by Bertozzi also are being used in the biopharmaceutical industry to generate engineered protein drugs including antibody-drug conjugates.

Luke Lavis, a chemist at HHMIs Janelia Research Campus first heard about Bertozzis work while he was working in industry. It was clear that this idea of bioorthogonal chemistry was going to be a major part of the then-nascent field of chemical biology, he says. At the time, Lavis synthesized the first commercial lot of some of Bertozzis molecules. Now, he says, the many reactions her lab developed permeate every corner of modern chemistry.

Bertozzi prides herself on choosing projects that many other chemists would consider too risky. We like to do things that some people might say are really out there,she said. In 2021, her team reported the surprise finding that sugar-coated RNA molecules decorate the surface of cells. In what Bertozzi describes as probably the biggest scientific shock of my life, she and her now-former postdoc Ryan Flynn showed that the so-called glycoRNAs poke out from mammalian cells outer membrane, where they can interact with other molecules.

The researchers work upended the current understanding of how the cell handles RNAs and glycans. Flynn is now running his own lab at Boston Childrens Hospital and Harvard University and plans to study how and if glycoRNAs are involved in immune signaling.

Bertozzi says the freedom to pursue an unlikely observation made the glycoRNA discovery possible. Thats what HHMI provided, she said. If I were a junior scientist who stumbled into this and put out an NIH grant, wed get laughed out of the study section.

Her enthusiasm for research and her talent for communicating science in the classroom has been recognized with multiple teaching awards. Bertozzi likens teaching to telling a story, and her goal for each lecture is to tell a memorable anecdote. For example, in a class she has taught frequently an introductory chemistry course for non-chemistry majors she has explained that her philosophy is to recapture in each lecture the thrill I felt when it was revealed to me that molecules are as diverse as human beings.

Bertozzi, Meldal, and Sharpless will split the 10 million Swedish kronor (roughly $900,000) for this years prize.

Bertozzi is the eighth woman to be honored with a Nobel Prize in Chemistry. The first was Marie Curie in 1911, for her discovery and work on the radioactive elements radium and polonium.

Bertozzi is now one of 34 current or former HHMI scientists who have won the Nobel Prize. In 2021, HHMI Investigator Ardem Patapoutian shared the 2021 Nobel Prize in Physiology or Medicine with David Julius for their discoveries of receptors for touch and temperature. In 2020, HHMI Investigator Jennifer Doudna shared the Nobel Prize in Chemistry with Emmanuelle Charpentier for developing a method of genome editing known as CRISPR-Cas9.

###

HHMI is the largest private biomedical research institution in the nation. Our scientists make discoveries that advance human health and our fundamental understanding of biology. We also invest in transforming science education into a creative, inclusive endeavor that reflects the excitement of research. HHMIs headquarters are located in Chevy Chase, Maryland, just outside Washington, DC.

See original here:
HHMI Investigator Carolyn Bertozzi Awarded the 2022 Nobel Prize in Chemistry | HHMI - Howard Hughes Medical Institute

Cell Isolation Global Market Report 2022: Significant Growth in the Medical and Pharmaceutical Industries Driving Sector – ResearchAndMarkets.com -…

DUBLIN--(BUSINESS WIRE)--The "Cell Isolation Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.

The global cell isolation market size reached US$ 10.3 Billion in 2021. Looking forward, the publisher expects the market to reach US$ 24.6 Billion by 2027, exhibiting a CAGR of 15.62% during 2021-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.

Cell isolation, or separation, refers to the process of identifying and removing one or more specific cells from a heterogeneous mixture of cell population. The targeted cells are identified, isolated and separated according to their type. Some commonly used methods for cell isolation include magnet-activated cell separation, filtration, centrifugation and flow cytometry.

Cell isolation is also used to diagnose diseases, cellular research and therapies by analyzing the ribonucleic acid (RNA) expressions. It aids in minimizing experimental complexity while analyzing the cells and reducing the interference from other cell types within the sample. As a result, it finds extensive application in cancer research, stem cell biology, immunology and neurology.

Cell Isolation Market Trends:

Significant growth in the medical and pharmaceutical industries is one of the key factors creating a positive outlook for the market. Furthermore, increasing emphasis on cell-based research is providing a thrust to the market growth. Researchers actively utilize isolated cells to develop novel cell therapies and cell-based treatments for various chronic medical ailments. Pharmaceutical manufacturers are also widely using cell isolation technologies to improve drug discovery and develop drugs with enhanced efficacies. In line with this, the increasing requirement for personalized medicines is also contributing to the growth of the market.

Additionally, the development of advanced separation tools for proteins, nucleic acids, chromatin and other complex cells for subsequent analysis is also contributing to the growth of the market. Other factors, including extensive research and development (R&D) activities in the field of biotechnology, along with the implementation of favorable government policies, are anticipated to drive the market toward growth.

Key Market Segmentation

Breakup by Technique:

Breakup by Cell Type:

Breakup by Product:

Breakup by Application:

Breakup by End Use:

Breakup by Region:

Key Questions Answered in This Report:

Key Topics Covered:

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Introduction

5 Global Cell Isolation Market

6 Market Breakup by Technique

7 Market Breakup by Cell Type

8 Market Breakup by Product

9 Market Breakup by Application

10 Market Breakup by End Use

11 Market Breakup by Region

12 SWOT Analysis

13 Value Chain Analysis

14 Porters Five Forces Analysis

15 Price Analysis

16 Competitive Landscape

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/8hx8ne

Follow this link:
Cell Isolation Global Market Report 2022: Significant Growth in the Medical and Pharmaceutical Industries Driving Sector - ResearchAndMarkets.com -...

Researchers find tumor microbiome interactions may identify new approaches for pancreatic cancer treatment – EurekAlert

Investigators from Rutgers Cancer Institute of New Jersey, the states leading cancer center and only National Cancer Institute-Designated Comprehensive Cancer Center, together with RWJBarnabas Health, examined the microbiome of pancreatic tumors and identified particular microorganisms at single cell resolution that are associated with inflammation and with poor survival. According to the researchers, these microorganisms may be new targets for earlier diagnosis or treatment of pancreatic cancer, which is the fourth leading cause of cancer death for both men and women in the United States. The findings are published in the online version of Cancer Cell (10.1016/j.ccell.2022.09.009).

Microbes are living things that are too small to be seen with the naked eye. We have more microbes living in our body than the total number of human cells, and can be found in organs like the pancreas, which at one time was considered microbe-free. Subhajyoti De, PhD, principal investigator at Rutgers Cancer Institute and senior author of the study along with graduate student Bassel Ghaddar, a student in the MD/PhD program at Rutgers Robert Wood Johnson Medical School, began exploring if there are microbes residing in pancreatic tumors, and if they have consequences for cancer progression or treatment. However, studying microbes in tumors is difficult, in part since every patient is different, and because microbial footprints are too subtle to detect reliably.

To explore further, the researchers teamed up with Martin Blaser, MD, Henry Rutgers Chair of the Human Microbiome at Rutgers University and world-renowned microbiome expert. The investigators developed a genomic approach called SAHMI (Single-cell analysis of Host-Microbiome Interactions) to identify microorganisms associated with individual human cells. Sifting through millions of RNA sequences using sophisticated software, they identified which ones likely represent human genes, and which ones are microbial in origin. This new technique allowed us to identify tumor-associated microbes and measure the activity of the host cells at the same time, which is a significant technical advance, and the results were stunning, notes Dr. De, who is also an associate professor of cancer systems biology at Rutgers Robert Wood Johnson Medical School.

Studying two independent groups of pancreatic tumors, the team found that some had bacteria that associated with specific cell-types within the tumor, which were essentially absent in normal pancreatic tissues. These bacteria were predominantly located within tumor cells, and their abundance correlated with cancer-related cell activities. The specific signatures of the microbes that were found predicted particularly aggressive cancer progression and poor prognosis.

The microbial footprints within the pancreatic tumors raised the question of whether the immune cells that were present were responding to the cancer or to the microbes. The study findings suggested that the immune responses were mostly responding to the microbes in the tumor and not to the cancer cells. Our observations provide a new view about why pancreatic cancers are so difficult to treat, notes Dr. Blaser, who is also a research member at Rutgers Cancer Institute and professor of epidemiology and biostatistics at Rutgers School of Public Health. But better understanding these interactions may identify new approaches for therapies.

Along with Drs. De, Ghaddar, and Blaser, other investigators include: Antara Biswas, PhD, Center for Systems and Computational Biology, Rutgers Cancer Institute; Chris Harris, PhD, Department of Surgery, University of Rochester Medical Center; M. Bishr Omary, PhD, Center for Advanced Biotechnology and Medicine, Rutgers University and Darren R. Carpizo, MD, PhD, Department of Surgery, University of Rochester Medical Center.

About Rutgers Cancer Institute of New Jersey

As New Jerseys only National Cancer Institute-designated Comprehensive Cancer Center, Rutgers Cancer Institute, together with RWJBarnabas Health, offers the most advanced cancer treatment options including bone marrow transplantation, proton therapy, CAR T-cell therapy and complex surgical procedures. Along with clinical trials and novel therapeutics such as precision medicine and immunotherapy many of which are not widely available patients have access to these cutting-edge therapies at Rutgers Cancer Institute of New Jersey in New Brunswick, Rutgers Cancer Institute of New Jersey at University Hospital in Newark, as well as through RWJBarnabas Health facilities. To make a tax-deductible gift to support the Cancer Institute of New Jersey, call 848-932-8013 or visitwww.cinj.org/giving.

Observational study

Cells

Tumor microbiome links cellular programs and immunity in pancreatic cancer

10-Oct-2022

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

Continue reading here:
Researchers find tumor microbiome interactions may identify new approaches for pancreatic cancer treatment - EurekAlert